Abstract
Synthetic cannabinoids (SCBs) are a popular new class of designer drugs. In 2018, the Centers for Disease Control and Prevention advised that illicit products containing SCB compounds were laced with brodifacoum (BDF), a highly potent superwarfarin easily purchased as a rodenticide. Multiple outbreaks of bleeding from BDF exposure have since been reported. Patients with BDF toxicity present with bleeding ranging from mild epistaxis to life-threatening hemorrhage. Given the increasing popularity of SCBs as recreational drugs, outbreaks from BDF exposure are likely to continue, presenting a public health risk. The nurse practitioner has a vital role in the complex, ongoing management of this patient population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
